Mircera - 2007 FDA approvals

Drug: Mircera
Indication: Anemia
Company: Roche
Approval Date: November 14, 2007

Scoop: Mircera has a longer half-life than other commercially available erythropoiesis-stimulating agents (ESA). However, Roche lost a patent infringement case to Amgen, which markets the bestselling--and controversial--anti-anemia drugs Aranesp and Epogen. Though Mircera is available overseas, for the forseeable future it will not be marketed in the U.S.

More news:
Mircera gets FDA nod, but blocked by patent case. Report
Roche: Patent ruling won't stop Mircera. Report
Roche to Launch Mircera in UK and Germany. Report

Mircera - 2007 FDA approvals
Read more on

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.